Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
A 76.19 0.30% 0.23
BMY closed up 0.3 percent on Friday, May 20, 2022, on 1.11 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Gapped Up Strength 0.00%
Fell Below 20 DMA Bearish 0.30%
Slingshot Bullish Bullish Swing Setup 0.30%
Bollinger Band Squeeze Range Contraction 0.30%
Gapped Down Weakness 0.30%
Bollinger Band Squeeze Range Contraction -1.08%
New 52 Week High Strength -1.08%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bristol-Myers Squibb Company Description

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Biopharmaceutical Diabetes Clinic Cancer Treatment Pharmaceutical Products Hypertension Melanoma Rheumatoid Arthritis Schizophrenia Hepatitis B Multiple Myeloma Stroke Dystrophy Serious Diseases Epidermal Growth Factor Receptor Organic Chemistry Depressive Disorder Hepatitis C Immunodeficiency Hepatitis B Virus Diabetic Nephropathy Hepatitis C Virus Biopharmaceutical Products Atrial Fibrillation Interferon Treatment Of Diabetes Heart Attack Metastatic Melanoma Hepatitis C Virus Infection Transplant Rejection Treatment Of Hypertension Chronic Myeloid Leukemia Kidney Transplant Leptin Lipodystrophy

Is BMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 78.465
52 Week Low 53.225
Average Volume 14,523,433
200-Day Moving Average 65.55
50-Day Moving Average 74.78
20-Day Moving Average 76.22
10-Day Moving Average 76.51
Average True Range 1.54
RSI 51.69
ADX 15.9
+DI 20.91
-DI 19.99
Chandelier Exit (Long, 3 ATRs) 73.86
Chandelier Exit (Short, 3 ATRs) 77.97
Upper Bollinger Bands 77.68
Lower Bollinger Band 74.76
Percent B (%b) 0.49
BandWidth 3.84
MACD Line 0.48
MACD Signal Line 0.62
MACD Histogram -0.133
Fundamentals Value
Market Cap 172.17 Billion
Num Shares 2.26 Billion
EPS 0.51
Price-to-Earnings (P/E) Ratio 148.52
Price-to-Sales 3.46
Price-to-Book 2.78
PEG Ratio 0.82
Dividend 1.80
Dividend Yield 2.36%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 78.91
Resistance 3 (R3) 78.92 78.04 78.45
Resistance 2 (R2) 78.04 77.35 78.03 78.30
Resistance 1 (R1) 77.11 76.92 76.67 77.10 78.15
Pivot Point 76.23 76.23 76.01 76.22 76.23
Support 1 (S1) 75.30 75.54 74.86 75.29 74.23
Support 2 (S2) 74.42 75.11 74.41 74.08
Support 3 (S3) 73.49 74.42 73.93
Support 4 (S4) 73.48